TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia, non-small cell lung cancers, gastrointestinal stromal tumors, and HER2-positive breast cancers. Here, ERBB2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.